Lilly Reports 'Unfortunate' Study Results

Posted: Updated:
INDIANAPOLIS -

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) says results of a Phase 3 study for the drug Verzenio did not meet its primary endpoint in the treatment of advanced lung cancer. The drug, also known as abemaciclib, has already received FDA approval as a treatment for breast cancer.

Lilly says the JUNIPER study evaluating Verzenio was designed to evaluate the efficacy and safety of the drug in patients with state IV non-small lung cancer who have received chemotherapy. Levi Garraway, senior vice president of global development and medical affairs for Lilly Oncology calls the outcome of the study "unfortunate."

"We remain encouraged by the antitumor activity observed with abemaciclib in this form of lung cancer where few clinical advances have been achieved," said Garraway. "As we analyze secondary endpoints and explore specific patient subgroups in order to better evaluate the prospects for abemaciclib in NSCLC, we will continue to work with the oncology community to inform potential future treatment avenues for patients with KRAS-mutated advanced lung cancer. Moreover, we have several studies ongoing of rational combinations that include abemaciclib in non-small cell lung cancer and other malignancies. We look forward to seeing the results of these studies."

Lilly says it will submit the data from the duty at a medical meeting in 2018. You can read more about the results by clicking here.

  • Perspectives

    • Richardson is a senior manager with Centric Consulting.

      Marketing and Sales Alignment – Easier Than You Think

      There was a time, and perhaps you’re still living in it, where marketing is expected to drive sales leads, conversations, magically help close deals, and all sorts of expectations a marketing team can never meet. This period exists because there is a misalignment in those expectations of what marketing should do and what sales should do. I like to start with the basics. Is your company providing a product or service? Is it easy to sell? Is it cheap? Do your customers buy once?

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • Wesemann Hall at the Valparaiso University Law School (photo courtesy Tony V. Martin/The Times of Northwest Indiana)

      Valpo School of Law Transfer Denied

      A proposal to transfer Valparaiso University's law school to another university has been shot down. The Tennessee Higher Education Commission has denied the transfer to Middle Tennessee State University, which would have led to the creation of a College of Law at the school. 

    • Daniels Envisions Purdue, Region as 'Cooler Place'

      Purdue University President Mitch Daniels says a more than $1 billion live, work, play development on the West Lafayette campus will be a magnet for attracting and keeping top talent in the region. The Discovery Park District is part of a 30-year vision to transform the west side of the Purdue campus and create a "preeminent environment" for educational, economic, cultural and community activities in the region.

    • Manufacturer to Close in Muncie

      Illinois-based JD Norman Industries is planning to close its facility in Muncie. In a notice to the state, the company says the decision will result in the layoffs of 130 employees. JD Norman did not provide a reason for the closure.

    • Mega-Merger Involves Fort Wayne Operation

      A defense industry contractor with a significant presence in Fort Wayne has announced a merger agreement. Florida-based Harris Corp. (NYSE: HRS) and L3 Technologies Inc. (NYSE: LLL) in New York say the combination will create the sixth-largest defense company in the country. In early-2015, Harris completed the $4.75 billion acquisition of Exelis, a long-time manufacturer of military radio technology in Fort Wayne. Shortly after the acquisition, Harris consolidated...

    • Ambrose: White River to be Centerpiece of $1.4B Project

      The Indianapolis-based developer of the city's former GM Stamping Plant site says it's excited about the $1.4 billion downtown district sitting next to a "major natural asset." Ambrose Property Group Senior Vice President Andrew Greenwood says the Waterside development will embrace the White River, which he believes "historically the city and the state have kind of turned their back on." He says the river will provide recreational opportunities at Waterside...